Abnormal serum transaminase levels in patients with hemophilia A.
In a cooperative study of 1,332 hemophiliacs, the results of a variety of liver function tests were correlated with the intensity and type of exposure to plasma products. After three sets of measurements of six-month intervals, 72% of patients had at least one abnormal transaminase value and 21.1% and 23.6% of patients had persistently elevated SGOT and SGPT levels, respectively, on all three measurements. Patients who had received no factor VIII during the previous year had fewer abnormalities than treated patients. Only those treated patients who received less than 50 units of factor VIII per kilogram per six months had fewer transaminase abnormalities if they used cryoprecipitate than if they used concentrate, but these patient groups are not strictly comparable, in that the cryoprecipitate-treated group contained a higher proportion of patients with mild hemophilia than did the concentrate-treated group.
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D005169:Factor VIII / Q000592:standards / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy / Q000201:enzymology*; D006801:Humans; D008111:Liver Function Tests; D000637:Transaminases / Q000097:blood*
D005169:Factor VIII; D000637:Transaminases; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase